Kelly McQuarrie
Overview
Explore the profile of Kelly McQuarrie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aguiar-Ibanez R, McQuarrie K, Jayade S, Penton H, DiGiovanni L, Raina R, et al.
Future Oncol
. 2024 Dec;
21(3):349-365.
PMID: 39676564
Background: Following an early-stage cancer diagnosis, recurrences can occur. To quantify financial impacts of a first recurrence, we surveyed patients and caregivers. Methods: The survey was self-administered online to patients...
2.
Chan E, Williams V, Romano C, Fehnel S, Slagle A, Stoddard J, et al.
J Patient Rep Outcomes
. 2023 May;
7(1):45.
PMID: 37195456
Background: The Symptoms of Infection with Coronavirus-19 (SIC) is a 30-item patient-reported outcome (PRO) measure scored by body system composites to assess signs/symptoms of coronavirus disease 2019 (COVID-19). In addition...
3.
Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K
Influenza Other Respir Viruses
. 2023 Feb;
17(2):e13100.
PMID: 36824394
Respiratory syncytial virus (RSV) is responsible for over 30 million lower respiratory tract infections (LRTIs) and 3 million hospitalizations worldwide each year. Despite the risk RSV poses to young children,...
4.
Romano C, Mayorga M, Ruiz-Guinazu J, Trudel G, Fehnel S, McQuarrie K, et al.
J Patient Rep Outcomes
. 2023 Jan;
7(1):7.
PMID: 36701073
Background: The Symptoms of Infection with Coronavirus-19 (SIC) is a 30-item patient-reported outcome measure to evaluate the presence and severity of COVID-19 signs/symptoms in adults. This study expanded the context...
5.
Aggarwal R, Alumkal J, Szmulewitz R, Higano C, Bryce A, Lopez-Gitlitz A, et al.
Prostate Cancer
. 2022 Oct;
2022:5454727.
PMID: 36212187
Purpose: This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer...
6.
Romano C, Fehnel S, Stoddard J, Sadoff J, Lewis S, McNulty P, et al.
J Patient Rep Outcomes
. 2022 Jul;
6(1):85.
PMID: 35904710
Background: Given the urgent need for vaccines and treatments for coronavirus disease 2019 (COVID-19), the Symptoms of Infection with Coronavirus-19 (SIC), a comprehensive, patient-reported outcome (PRO) measure of signs and...
7.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 Jul;
206(4):923.
PMID: 34296946
No abstract available.
8.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 May;
206(4):914-923.
PMID: 34039013
Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo,...
9.
Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, et al.
Adv Ther
. 2019 Dec;
37(1):512-526.
PMID: 31813087
Introduction: The present study aimed to indirectly compare apalutamide and enzalutamide with respect to tolerability and health-related quality of life (HRQoL) among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Methods:...
10.
Condon D, Chapman R, Shaunfield S, Kallen M, Beaumont J, Eek D, et al.
Qual Life Res
. 2019 Nov;
29(3):745-753.
PMID: 31701432
Purpose: To evaluate the influence of recall periods on the assessment of physical function, we compared, in cancer and general population samples, the standard administration of PROMIS Physical Function items...